Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 3Terminated 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 1Genitourinary 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 35Prostatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 30Breast Neoplasms 27Lymphoma 20Lymphoma, Non-Hodgkin 18Hematologic Neoplasms 14Squamous Cell Carcinoma of Head and Neck 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Sarcoma 11Neoplasm Metastasis 11Pancreatic Neoplasms 10Neoplasms 10Lung Neoplasms 10Leukemia, Myeloid, Acute 10Head and Neck Neoplasms 10Colorectal Neoplasms 10Carcinoma, Renal Cell 10Triple Negative Breast Neoplasms 9Ovarian Neoplasms 9Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Glioma 8Wilms Tumor 7Urinary Bladder Neoplasms 7Stomach Neoplasms 7Sarcoma, Ewing 7Rhabdomyosarcoma 7Rhabdoid Tumor 7

Interventions

tremelimumab 1pevonedistat 1durvalumab 1cabozantinib 1Taxes 1Specimen Handling 1Simvastatin 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Liver Transplantation 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Carcinoma, Hepatocellular × 30 days × Clear all
NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT04175912 2026-05-20

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

NCT02968810 2026-05-04

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

National Cancer Institute (NCI)

Phase 2 Active not recruiting
52 enrolled 15 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡